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Abstract: Hepatocellular carcinoma (HCC) is the fifth most common type of cancer diagnosed and
the second leading cause of death worldwide. Despite advancement in current treatments for HCC,
the prognosis for this cancer is still unfavorable. This comprehensive review article focuses on all the
current technology that applies biomaterials to treat and study liver cancer, thus showing the versatility
of biomaterials to be used as smart tools in this complex pathologic scenario. Specifically, after
introducing the liver anatomy and pathology by focusing on the available treatments for HCC, this
review summarizes the current biomaterial-based approaches for systemic delivery and implantable
tools for locally administrating bioactive factors and provides a comprehensive discussion of the
specific therapies and targeting agents to efficiently deliver those factors. This review also highlights
the novel application of biomaterials to study HCC, which includes hydrogels and scaffolds to tissue
engineer 3D in vitro models representative of the tumor environment. Such models will serve to
better understand the tumor biology and investigate new therapies for HCC. Special focus is given to
innovative approaches, e.g., combined delivery therapies, and to alternative approaches—e.g., cell
capture—as promising future trends in the application of biomaterials to treat HCC.
Keywords: biomaterials; hepatocellular carcinoma; 3D models; nanoparticles; microparticles;
immunotherapy; scaffolds
1. Introduction
Biomaterials have recently become a powerful tool for the treatment and study of tumors,
including liver cancer. The peculiarity of using biomaterials for cancer relies on the variety and
versatility of their properties, which allow size, surface charge and chemistry, shape, morphology, and
physiochemical properties, to be tuned according to target applications. Being processable from the
nano- to the macro-scale, biomaterials-based technologies can tremendously support the therapies
available for liver cancer and the comprehension of this disease by enabling advanced in vitro models.
In this review, we provide a comprehensive overview of the biomaterial-based approaches released
or under development for liver cancer. Starting from a framework of the liver microenvironment,
including normal and neoplastic tissue, and the current treatment methods available for hepatic tumors,
this review focuses on highlighting the biomaterials-based therapies that have been developed for liver
Cancers 2019, 11, 2026; doi:10.3390/cancers11122026 www.mdpi.com/journal/cancers
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cancer, which encompass materials used for systemic and local delivery. A discussion of the bioactive
factors and targeting agents which have been applied in biomaterial-based therapies is a subject of this
review. In the second part, we describe and discuss those biomaterial-based applications that mimic a
liver cancer microenvironment to better study hepatic cancer.
This review aims to provide a thorough discussion on the multiscale application of biomaterials for
liver cancer. Nano-to-micro range biomaterials are generally used for treatment, whereas, macroscale
materials, in the form of tissue engineering scaffolds, are used for study this tumor. There are many
review articles on nanotechnology/nanomedicine for liver cancer therapy, such as nanoparticles
(NPs) and liposomes [1–8], liver cancer diagnosis and therapy [9], and biomaterials used for targeted
systems [10]. However, there are no comprehensive reviews of biomaterial-based therapy that includes
an overview of materials in the nano-to-macro domain, which also includes microparticles and scaffolds,
with a discussion of both systemic and local delivery applications. To the best of our knowledge, there
are no reviews that also discuss the application of biomaterials for 3D systems to better study liver
cancer, and in particular hepatocellular carcinoma (HCC). This review article aims at summarizing and
discussing the state-of-the-art biomaterials used to treat and study HCC to provide a comprehensive
and influential scientific base to support future strategic directions in the therapies of this dismal tumor.
2. Liver Structure and Function
Liver is a solid organ which is located under the diaphragm in the upper right quadrant of the
abdominal cavity. It is closely associated with the small intestine in order to process the venous blood
derived from the digestive tract. The liver performs a number metabolic functions, such as bile secretion,
bilirubin and nutrient (e.g., fats, proteins, carbohydrates) metabolism, metabolic detoxification, mineral
and vitamin storage, as well as some endocrine and immune functions. As a consequence of its key
metabolic role, liver pathology, either acute or chronic, can lead to severe outcomes that may progress
to death [11]. From an anatomic point of view, human liver is divided into four lobes designated as
left, right, caudate, and quadrate. The liver also contains the gallbladder, a sac-like structure for bile
accumulation. Every lobe of the liver is divided into lobules by connective tissue branches departing
from the connective capsule that covers the liver. These connective septa form the liver stroma, which
supports the parenchyma, containing the liver cells, hepatocytes, and act as a scaffold for the blood and
lymphatic vessels, and bile ducts. The “hepatic lobule” is the anatomic model used to represent liver
lobules [12]. It has a hexagonal-like shape into which hepatocytes are arranged as plates departing
from the central vein in the central axis of each lobule. The vertices of the lobules are characterized by
the presence of the portal triads: each triad contains a branch of the portal vein and of the hepatic
artery and a bile duct (Figure 1).
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In the lobule, it is possible to identify the so-called ‘liver acinus’ that is defined as a mass of
hepatocytes aligned around the arteriolar and venous blood flow of the portal triads. In this unit,
hepatocytes can be divided into three zones, which have different functionalities related to their
distance from the oxygen supply. Hepatocytes belonging to the zone 1 are those cells which receive the
largest blood supply due to their proximity to the hepatic artery and portal vein branches. Liver cells
belonging to zone 2 receive a lesser blood supply, and the hepatocytes in zone 3 are the most sensitive
to hypoxia (Figure 1).
Another morphological representation of liver parenchyma is the “portal lobule”, which takes
into account the liver biliary excretion function. This structure is represented by a triangle with three
adjacent central veins as vertices and a portal triad in the center. Bile is drained from the central veins
towards the bile duct of the portal triad (Figure 1).
The liver receives about 80% of the blood from the portal vein, which drains all the blood from
intestine, and 20% of the blood from hepatic artery. Blood from these vessels mixes together into
sinusoids and flows towards the hepatic vein that brings the blood into the inferior vena cava (IVC)
and then to all the body. Hepatocytes represent roughly the 60% of the liver cells; they are often
binucleated, and can perform diverse functions, including the metabolism of carbohydrates, lipids
and proteins; the production of bile, albumin, and of coagulation factors; as well as the metabolism
of steroid hormones and of xenobiotic drugs. Hepatocytes have a sinusoidal face which is directly
soaked by the blood flowing into the sinusoids while their lateral faces are in contact to each other
and partially modified to form bile canaliculi that convey bile into the bile ducts and finally into the
gallbladder. Hepatocyte morphology and function vary depending on their proximity to the periportal
or to the pericentral zone as described above [12].
Liver also hosts the so-called hepatic progenitor cells (HPCs), known as oval cells (OCs) in
rodents, that are considered intra-hepatic precursor cells able to proliferate and differentiate into
the two epithelial lineages of the liver—namely, hepatocytes and cholangiocytes—when hepatocyte
proliferation is impaired or suppressed [13,14]. Furthermore, in the liver sinusoids, Kupffer cells,
which have a phagocytic activity whereas, in the space of Disse (i.e., between the sinusoidal face of the
hepatocytes and the sinusoidal endothelial cells), stellate cells (also known as Ito cells) which store
vitamin A and are able to regulate inflammatory responses, can be found (Figure 2) [15].
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3. Liver Neoplasia
Liver tumors are a heterogeneous neoplasia with a great clinical relevance due to morbidity and
mortality rates. Hepatic neoplasms can be classified as: (1) primary tumors, when derived from the
liver parenchyma such as hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCC),
fibrolamellar carcinoma and hepatoblastoma (an early liver tumor in children); and (2) secondary
tumors, when derived from metastatic cells of other tumors (e.g., colorectal, pancreas, stomach, breast,
ovary cancers, and so on) [16].
Among all these neoplasms, HCC is the most common and a constantly increasing incidence in
the last decades. HCC has become the fifth most common cancer diagnosed and the second leading
cause of death in the world, with prevalent mortality rates in men [16].
The most frequent risk factors for HCC development are chronic infections with hepatitis B virus
(HBV) and C virus (HCV), even though in the last years they have become less significant among
young people [17]. The vaccination campaigns to prevent HBV, new pharmacological treatments,
early diagnosis, and a more diffuse knowledge on the possible transmission routes of these virus,
have led to a decrease of chronic viral liver diseases. Nevertheless, other risk factors for HCC have
demonstrated a growing incidence, such as diabetes, obesity, alcohol and tobacco consumption,
metabolic disease, heritable syndromes, and aflatoxins. Such factors are indeed prevalent in some
areas of the world—such as Europe, and North and Latin America—where HCC shows an unfavorable
growing trend. Differently, in East Asia, where HCC mainly occurs from viral infections or aflatoxins
exposure, a decrease or steady trend has been identified [17].
3.1. Diagnosis
Thanks to the advanced imaging techniques, surveillance guidelines and follow up programs
have been established in different countries for patients with chronic liver disease of any etiologies, to
perform tumor diagnosis and staging. Ultrasound is the primary screening method used to evaluate
liver integrity and identify hepatic lesions. Other imaging techniques, such as the contrast-enhanced
computer tomography (CT) or magnetic resonance imaging (MRI), are employed to improve the
diagnosis and describe the staging of the tumor [18]. These radiological methods established criteria
which allow liver lesions and staging systems set up for HCC, such as the Barcelona-Clinic Liver Cancer
(BCLC) (Figure 3), to be categorized, thus helping the correct diagnostic evaluation [19]. Nevertheless,
atypical imaging appearance may require histological analysis.
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The immunohistochemical detectio f a tigens, such as Glypican 3, heat shock protein 70,
glutamine synthetase and clathrin heavy chai , ed to confirm the diagnosis for HCC. Biopsy can
fail to achieve sufficient sensitivity and specifi i ue to sampling errors or differenti l diagnosis
misunderstanding (e.g., between early-stage CC and dysplastic nodules) [20]. Genomic expression
profiles have extensively been described for HCC, by means of new biomolecular technologies, namely,
microarrays and next-generation sequences (NGS) and correlation between the expression of molecular
markers and pathological features, etiology, and clinical outcomes have been proposed [19]. Despite
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these developments, up to now there are no therapies targeting the major mutations of HCC and no
biomarkers able to predict the real response to a specific therapy [21]. To date, protocols of study and
evaluation of tumor staging have been drawn up, making it possible to identify the most appropriate
therapeutic intervention. BCLC criteria are the most used to establish HCC staging as they consider
the tumor characteristics, the performance status of the patient and the liver functional status; finally,
they suggest a potential treatment which can increase the patient’s benefit and survival. The staging
classification and the treatment schedule can be applied to the majority of HCC patients, although a
special consideration has to be warranted to patients with impaired liver function who are candidate
for liver transplantation [22]. Based on the staging of HCC, different treatments can be applied to treat
this disease.
3.2. Current Treatment Methods
3.2.1. Surgical Resection
This treatment has the best performance in patients in very early or early stages of the tumor
(BCLC 0-A), without cirrhosis and with variable tumor size, although the tumor extension is a poor
prognostic factor [23]. New algorithms for surgical strategies have been proposed to treat HCC patients
with BCLC stages B and C by considering the tumor burden, the functionality of the liver reserve and
the volume of the remnant liver. There are different scoring systems for estimating liver functional
reserve, including Child–Pugh–Turcotte (CPT), the model for end-stage liver disease (MELD), and the
aspartate transaminase-to-platelet ratio index (APRI). However, the predictive potential and the results
produced by their application are not homogeneous since they do not take into account the patient’s
performance status. Recently, the serum bilirubin/serum cholinesterase (BILCHE) scoring system has
successfully been applied for selecting patients who can undergo surgical resection with a low risk of
postoperative complications [24]. Currently, only a low percentage of well-selected patients can benefit
of surgical resection. Recurrences after this approach are unfortunately frequent due to microscopic
vascular invasion and tumor dissemination or de novo tumor formation. Adjuvant therapies applied
after surgical resection, such as internal radiation therapy or immunotherapy, have been shown to
reduce recurrence of tumors, thus prolonging the overall survival [25–27].
3.2.2. Liver Transplant
Live transplant is the gold standard treatment in patients with liver cirrhosis and with tumor
lesions that subside into Milan criteria (MC) (i.e., patients who have a single tumor mass greater than
5 cm, or up to three lesions of 3 cm each). MC have been proposed by Mazzaferro et al. in 1996 [28],
and were adopted globally to select patients for liver transplantation: their application has resulted
in a 75% patients with a 5-year overall survival rate and only a 15% patients with tumor recurrence.
Although these criteria have been considered too restrictive, it has been observed that tumors exceeding
the MC have a higher recurrence and an increased risk to develop different tumor type leading to a
poor prognosis against those that fulfill MC. Indeed, many studies proposing expanded criteria still
require additional validation (UCSF, UCLA) [23].
3.2.3. Ablation
Ablation procedure is performed by injection of ethanol inside the tumor or by intratumor
radiofrequency which produce a necrotic area of about 3 cm diameter. It is a standard of care for
patients classified as BCLC A or 0 with tumor size less than 2 cm who cannot undergo or are considered
not to benefit from a surgical. Recently, microwave ablation has been applied in patients with larger
tumors showing a higher capability of inducing necrosis than radiofrequency. However, these tumor
treatments and other emerging ablative methods have shown a great efficacy only in small-size tumors
and present the same recurrence rate as observed after surgical resection [23,29].
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3.2.4. Chemoembolization
Transarterial chemoembolization (TACE) is a non-surgical procedure that combines embolization
with local delivery of drugs; as such, it is preferentially applied in patients with high HCC staging
(i.e., BCLC stage B) [29]. This therapeutic treatment has also been applied using drug-eluting beads
which can release the chemotherapeutic agent in a controlled manner by concentrating the drug in
the tumor site and reducing its systemic circulation. As an alternative to the use of chemotherapeutic
agents, the use of radioactive isotopes (i.e., radioembolization; RE) such as Yttrium-90 has recently
been proposed. The advantage of RE compared to TACE is that the microspheres used for RE have
a smaller size than the particles used for drug-eluting, thus reducing ischemia to the tumor and the
live tissue [29]. The best survival benefits from this procedure have been obtained in patients with
preserved liver function and without vascular or extrahepatic invasion of the tumor.
3.2.5. Chemotherapy
For patients classified as BCLC D, with advanced progression of HCC and metastasis, systemic
chemotherapy is the only treatment that can be applied to try to prolong overall survival. In the
latest years, the first line therapy is the chemotherapy drug Sorafenib (Sor) which is a tyrosine kinase
inhibitor (TKI). This drug functions by blocking cell surface tyrosine kinase receptors (TKRs) and/or
intracellular serine/threonine kinases, thus resulting in anti-angiogenic and anti-proliferative properties.
Sor treatment determines an increase of the overall survival and a delay in the progression of the
pathology. Despite these benefits, Sor has different severe side effects, such as diarrhea, arterial
hypertension, and dermatological adverse events like hand-foot skin reaction (HFSR), which may
require to stop the treatment [1]. Due to the limited efficiency of this therapy, other single therapeutic
agents have been investigated and are under study in clinical trials. Among different anti-angiogenic
TKI investigated in phase III trials, Lenvatinib has been demonstrated to reach a comparable or even
better efficacy than Sor. It has been considered as the alternative first line therapy for HCC treatment.
Nevertheless, also Lenvatinib can cause many adverse effects as hypertension, diarrhea anorexia,
fatigue, and weight loss [30].
In patients who do not tolerate Sor, Regorafenib, a multi-kinase inhibitor of vascular endothelial
growth factor receptor 1-3 (VEGFR1-3), has been approved as a second line therapy for HCC, due to the
survival benefits observed. In addition to multi-kinase inhibitors, different researches are evaluating
molecules able to block the different molecular pathways underlining hepatocarcinogenesis, or agents
that target the epigenetic dysregulation described for HCC. Tivantinib, which selectively inhibits
c-MET and HGFR, Everolimus, an mTOR inhibitor, or molecules which selectively block VEGFRs,
such as Axitinib or Apatinib are a subject of study. It has been observed that a single targeted agent is
less efficient than combination of multiple molecules for treating of HCC [31]. Nevertheless, it has
been observed that the combination of Sor with either TKI, such as erlotinib [32], or mammalian target
of rapamycin (mTOR) inhibitor (i.e., everolimus) [33], did not improve Sor efficacy. Moreover, the
combined therapy of Sor with the MAPK/ERK inhibitor Refametinib showed an increase in patient
survival but also caused grade 3 and 4 adverse events [34].
Together with the development of new pharmacological agents, many cytotoxic agents as
doxorubicin (DOX), cisplastin, 5-fluorouracil, and epirubicin have been also used as systemic therapy
for HCC but they did not show high improvements in overall survival and their combination caused
different side effects like an increase of myelotoxicity or neurotoxicity, neutropenia compared to the
single agent administration. Furthermore, different studies have investigated the combination of
therapies of Sor with TACE or with these systemic agents. They reported that the administration of Sor
in combination with one or more inhibitors may improve the benefits for the patient, although toxicity
and adverse effects may increase accordingly [31].
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3.2.6. Immunotherapy
Immune therapy has recently been introduced to treat HCC. The immune-based approach relies
on the observation that tumor cells can survive by escaping the immune system when they express,
on their surface membrane, the programmed cell death ligand 1 (PDL-1), which is able to bind the
programmed death-1 (PD-1) receptor on activated T cells. The interaction between these ligands leads
to the inactivation of T cells and consequently to the tumor cells survival [21]. Nivolumab is a human
monoclonal antibody currently used for different metastatic tumors: it has the ability to bind to PD-1
receptor interfering with the PDL-1 interaction and thus restoring the immunocompetence of T cells
against cancer. Similarly, Tremelimumab is used to block the cytotoxic T-lymphocyte antigen (CTLA-4),
allowing T cells to continue tumor cell destruction [35]. Clinical trials are ongoing to evaluate the
efficiency of these immune therapies as alternative treatments for HCC and point out the possible
adverse effects of their application either as single therapies or in combination with TACE or other
therapeutic approaches.
Recently, it has been observed that immunotherapy induced adverse effects such as rush,
fatigue, pruritis, and diarrhea and the increase of aspartate aminotransferase/alanine aminotransferase
worsening liver functionality. Cardiovascular toxicities have been also observed during the treatment
with immune checkpoint inhibitors [36]. Furthermore, in some cases, immune cell infiltration and a
delayed antitumoral response was demonstrated leading to the so called pseudoprogression of the
tumor [37].
Another therapeutic approach under evaluation for HCC treatment is based on the use of viruses
able to induce tumor cell death by activating the immune system. Second generation oncolytic human
herpes simplex virus type-1 has been genetically engineered to express the granulocyte macrophage
colony stimulating factor. It has been observed that oncolytic viruses are efficient against different
tumors blocking their growth and progression [38]. The induction of anti-tumor immunity using
tumor-associated antigens (TAAs) as peptide vaccines is a key research field, also applied to HCC [39].
For example, glypican protein 3 (GPC3) has been used as a potential peptide vaccine for its ability to
induce the cytotoxic T lymphocyte (CTL) response [40]. Furthermore, GPC3-derived epitope peptide
conjugated to liposomes seemed to be able to induce CTLs to inhibit the growth of GPC3-expressing
tumor [41]. Immune targeting of multi-drug resistance protein 3 (MRP3) was suggested to induce CTL
response against HCC cells which overexpress this transporter [42] and C-35 peptide from HCV-core
protein was shown to induce a specific IgG1 response [43].
3.2.7. Gene Therapy
MicroRNA (miRNA) and small-interfering RNA (siRNA) have been studied as nucleic acid-based
therapeutic drugs: miRNAs are non-coding single-strand molecules which act at post-translational
level or silencing RNAs [44]; siRNAs are double-stranded RNAs with the capability of specifically
targeting for degradation at several sites of antisense strand mRNA, thus knocking down the expression
of a specific gene [45]. The application of miRNAs and siRNAs is limited by their off-target effects that
can induce silencing of healthy genes. Moreover, delivery of these nucleic acids has many obstacles
such as nuclease degradation and body filtration [46]. In HCC, as in many tumors, miRNA profile
is altered compared to that of healthy subjects, showing both upregulation and downregulation of
miRNAs [47]. Some of these miRNAs are considered new possible biomarkers (e.g., miRNA-21),
while some others are potent tumor suppressors, like miRNA-34a, miRNA-29, and miRNA-122,
as they are downregulated in HCC patients [48,49]. As demonstrated by Deng and coauthors in
2011, their restoration can inhibit tumorigenesis using nanoparticles loaded with Rubone, a natural
compound able to upregulate miRNA-34a [50].
Cancers 2019, 11, 2026 8 of 41
4. Biomaterials for Drug Delivery in Liver Cancer
Cancer including HCC is a complex and diverse disease, which presents many challenges to
diagnose and treat it. The versatility and complex nature of biomaterials presents a promising approach
to address some of these challenges. Such biocompatible materials can be easily tailored and engineered
to be utilized to study, diagnose, and treat liver cancer by altering their different properties. Hereafter,
we discuss the different biomaterials that have been developed for improving drug delivery in HCC
applications, which are summarized in Table A1 (Appendix A).
4.1. Particles
4.1.1. Nanodiamonds
Nanodiamonds are approximately 5 nm in diameter and are made out of truncated semiotahderal
carbon structures [51]. By varying the surface electrical potential of the material by altering the
functional chemical groups on their surfaces, nanodiamonds can be used to load a wide range of
bioactive therapeutic factors for cancer therapy [52]. Nanodiamonds are more biocompatible and well
tolerated than other nanocarbon materials [53]. Wang et al. used nanodiamonds to deliver epirubicin,
a chemotherapeutic drug to chemo-resistant cancer stem cells [53]. As seen in Figure 4, the drug was
physically adsorbed onto the nanodiamonds. The nanodiamond-epirubicin particles resulted in a
nanodiamond aggregate diameter of 89.2 ± 3.3 nm.
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The epirubicin delivery with nanodiamonds resulted in enhanced endocytic uptake and tumor
cell retention compared to the drug delivered alone, and thus enhanced the killing of cancer stem cells
and non-cancer stem cells. The release from the nanodiamonds can be stimulated intracellularly by
charged proteins and thus ensuring intracellular-specific drug release which results in decrease in
toxic side-effects that can result from systemic delivery. These nanodiamonds are able to overcome
chemoresistance by prevention of the efflux of the drug by ABC transporters. Wang et al. demonstrated
that optimized nanodiamonds can efficiently load the drug, facilitate passive transport to cancer cells
and intratumoral release of the drug making it a pro ising candidate for hepatic cancer treatment.
4.1.2. PLGA-Based NPs
The copolym r poly(lactic-co-glycolic acid) (PLGA) is a polyester that is often used as a biomaterial
for the delivery of bioactive factors for different applications including cancer, due to its great
biocompatibility, biodegradability, and versatility [54,55]. Furthermore, the degradation rate of PLGA
can be optimized by altering the lactic to glycolic acid ratio, molecular weight and the end cap groups,
the latter also providing different options for drug affinity. PLGA has been used extensively for
drug delivery, including applications for the treatment of HCC. Ma et al. used PLGA NPs to deliver
5-fluoruracil for the treatment and imaging of HCC [56]. Besides using this copolymer by itself,
many groups have also used PLGA in combination with other polymers. Zhang et al. designed a
stepwise pH-responsive NP system containing charge reversible pullulan-based (CAPL) shell and
Cancers 2019, 11, 2026 9 of 41
poly(β-amino ester) (PBAE)/PLGA core to deliver paclitaxel (PTX) and combretastatin A4 (CA4), as a
combination antiangiogenesis and chemotherapy to treat HCC (Figure 5) [57].Cancers 2020, 12, x FOR PEER REVIEW 9 of 44 
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that the CAPL/PBAE/PLGA NPs exert i creased inhibit ry effects of PTX and CA4 n tumor
growth and angiogenesi . Xu et al. designed double-walled micro pheres that consisted of a
poly(D,L-lactic-co-glycolic acid) (PDLLGA) core surrounded by a poly(L-lactic acid) (PLLA) sh ll
layer [58]. The particles were loaded with the chemotherapeutic drug DOX i the core and chitosan-DNA
NPs containing the gene encoding th p53 tumor suppressor prot in (chi-p53) in the shell (Figure 6).
The combined treatment with DOX and chi-p53 demonstrated enhanced ytotoxicity as compared to
either DOX or chi-p53 treatments alone. The double- alled particles were prepared u ing a where
precision particle f brication (PPF) apparatus equipped with a coaxial n zzle th t produ e a jet of core
PDLLGA surrou ded by an annular stream of PLLA and allowed the simultaneous release of the two
bioactive factors.
Liang et l. used NPs synthesized with block copoly ers poly(γ-glutamic acid) (P ) and
oly(lactide) (PLA) to deliver PTX [59]. PGA is often incorpor ted as a biomaterial since it is
water solubl , biodegradable, non-toxic, and naturally occurring. The γ-PGA w s conjugated
with the active PLA to create the block polymer [59]. It w s then loaded and conjugated again
with the galactosamine as the targeting agent. These targeted NPs enhanced the tumor reduction
efficacy in comparison to on-targeting NPs and previously established/clinically available forms of
PTX. PLGA has also been used in combination with poly(ethylene glycol) (PEG), which is widely
applie in many biomedical applications due to its biocompatibility and high hydrophilic prop rties.
Ni t al. developed bi tin-/lactobionic acid–modified poly(ethylene glycol)-poly(lactic-co-glycolic
acid)-poly(ethylene glycol) (BLPP) copolymer NPs to deliver curcumin- and 5-fluorouracil [60].
The biotin a d l tobionic acid served as dual targeting agents and they were linked to the amphiphilic
triblock PEG-PLGA-PEG. Wang et al. used polyethylene glycol-block-polylactic acid (PEG-PLA)
amphiphilic copolymer assembled in water with oligo or polylactide-drug conjugates to deliver SN38
(7-ethyl-10-hydroxycamptothecin) [61]. Owing to its low solubility in water and dose-limiting toxicity,
SN38 use in the clinic is hinder d. Wang et al. used thes small-sized nd ultrastable nanomedicines
to deliver SN38 as b tter t lerated cy otoxic nanother py. The covalent conjugating of the rug
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augmented its retention in the PEG-PLA NPs. By increasing the length of the PLA chain, the retention
and antitumor activity was increased, enabling a complete eradication of the tumors in mice.
PLGA NPs have been widely used for cancer therapy; however, groups are moving towards
using a combination of PLGA with other synthetic or natural polymers to create optimal drug delivery
vehicles by leveraging the benefits of the different polymers. PLGA is very versatile in its ability to
adjust drug release rates; on the other hand, other polymers may be able to more efficiently load the
drugs of interest. For example, PBAE which has piperidine rings that can better carry the PTX and
CA4 drugs investigated by Zhang et al. [57]. However, PBAE alone is not a suitable polymer for drug
delivery, as it has poor stability in blood and has high positive charges [62]. Thus, combination with
PLGA, as shown by Zhang et al., resulted in NPs with enhance stability and adjustable release kinetics
due to the PLGA and better loading bioavailability due to the PBAE [57].Cancers 2020, 12, x FOR PEER REVIEW 10 of 44 
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4.1.3. Natural Polymers Particles
Natural polymer, unlike synthetic polymers, are naturally available in the environment. Gelatin is
a widely used and biocompatible protein, obtained as denatured collagen, that can be degraded by
metal matrix protease-2 (MMP2), which is over-expressed in tumors [63,64]. Liu et al. used gelatin
NPs to deliver DOX-lactose [65]. The NPs were constructed by self-assembly followed by crosslinking
of the gelatin (Figure 7). In fact, unlike collagen, non-crosslinked gelatin is soluble at 37 ◦C.
DOX-lactose molecules were then conjugated to the particles where lactose was utilized to target
HCC cells. The tumor extracellular matrix MMP2 leads to the degradation of the NPs and release of
DOX. In addition, there was a pH-responsive disassociation of DOX and lactose in the tumor cells,
resulting in free drug inside the cells. This method reduced the systemic toxicity generally produced
by DOX while increasing tumor inhibition rates. Hanes et al. used gelatin and chondroitin-6-sulfate
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microspheres to deliver interleukin-2 (IL-2) for immunotherapy [66]. This microsphere was created
using an aqueous-based complex coacervation process. Through the use of microsphere mediated
IL-2 release, prolonged liver-specific IL-2 exposure was observed. Hanes et al. demonstrated that the
microspheres were more effective than an optimized dose of autologous cells, which are currently
considered the gold standard for immunotherapy.
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Chitosan is a cationic polysaccharide which is manufactured commercially through partial
deacetylation of chitin [67]. Chitosan NPs (CNPs) are usually fabricated through cationic chitosan
ionotropic gelation with polyanion sodium tripolyphosphate. Qi et al. demonstrated that CNPs
not loaded with any drug have antitumor effect on HCC cells due to neutralization of cell surface
charge, decrease of mitochondrial membrane potential, and induction of lipid peroxidation [68].
CNPs cause death by disrupting the cell membrane, decreasing the negative surface charge and
mitochondrial membrane potential, inducing lipid peroxidation, disturbing the fatty acid composition
of the membrane and fragmenting DNA. Xu et al. further showed that CNPs inhibit tumor growth
through tumor angiogenesis impairment [67]. The vascular endothelial growth factor receptor 2
(VEGFR2) levels was decreased, resulting in blockage of VEGF-induced endothelial cell activation.
CNPs have also been used to deliver other molecules and drugs. For example, Bu et al. utilized these
particles to delivery trans-resveratrol [69], and Cheng et al. [70] utilized these particles for gene therapy.
Chitosan ability to induce cancer cell death by itself and act also as a drug delivery vehicle make it is a
very promising natural polymer for hepatic cancer treatment.
4.1.4. Metallic NPs
Metallic NPs such as iron, gold and silver have been used in different biomedical applications for
imaging and therapy. Magnetic iron NPs have the ability to be controlled by superparamagnetism,
allowing the regulation of their movement and concentration using an external magnetic
field [71]. Xue et al. utilized galactosylated-carboxymethyl chitosan-magnetic iron oxide NPs
(Gal-CMCS-Fe3O4-NPs) to deliver the tumor suppressor gene RASSF1A [72]. They were able to
improve the transfection efficiency of the particles by controlling the direction of travel of the super
paramagnetic iron oxide NPs. Kou et al. focused on ultrasmall superparamagnetic iron oxide (USPIO)
NPs conjugated with humanized SM5-1 antibody, which binds to HCC cells [73]. These particles can be
used as contrast agents for diagnosis by MRI. Gold NPs main accumulation site is in the liver, and thus,
it is a promising biomaterials for the treatment of liver cancer [74,75]. Gold NPs are usually capped with
either sodium citrate, polyamidoamine dendrimers (PAMAM), or L-aspartate to stabilize the particles
and their cellular uptake is usually mediated by clathrin dependent endocytosis. One advantage of
these microparticles are their anti-angiogenic properties by inhibiting endothelial and fibroblast cell
proliferation [76]. Tomuleasa et al. reported on gold NPs conjugated non-covalently with L-aspartate
and conventional chemotherapy drugs, cisplatin/DOX/capecitabin, to deliver this anti-tumor therapy
through endocytic uptake into the cells [77]. Ma et al. used gold NPs conjugated with the antibody
for SM5-1 which was stabilized using sodium nitrate [78]. Paino et al. [74] also studied gold NPs
which were capped with either sodium citrate or polyamidoamine dendrimers (PAMAM). Finally,
Xue et al. used gold NPs to deliver miRNA-375 [75]. Compared to other types of NPs, metallic NPs are
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promising for the treatment of hepatic cancer due to their ability to be controlled by an electromagnetic
field, their broad optical properties which make results in their ability to not only serve as a delivery
vehicle, but also as contrast agent for imaging.
4.1.5. Lipid-Based Particles
Liposomes are characterized by a lipid bilayer that is formed from self-assembly of amphipathic
phospholipids, resulting in an interior aqueous space. Gao et al. used DOTAP/Cholesterol liposome
conjugated with anti-EGFR to target HCC cells. These liposomes were used to deliver adriamycin and
ribonucleotide reductase M2 (RRM2) siRNA. Their results demonstrated that the targeting and dual
delivery of both drugs gave rise to enhanced therapeutic effects compared to non-targeted or single
drug liposomes. Wei et al. investigated liposomes made of soybean phosphatidylcholine/cholesterol
which was PEGylated to deliver DOX [79]. PEGylation is advantageous as it increases circulation
time and avoids rapid clearance by the reticuloendothelial system [80,81]. Lo et al. also applied
PEGylated liposomes to deliver DOX, but the exact construct is unknown [82]. Wang et al. used
immunoliposomes to delivery DOX [83]. They used commercially available Ls-DOX, but modified it
by adding 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000]
(DSPE-PEG-Mal) conjugated with Metuximab. Wang et al. also used liposomes, but the construct was
not specified. The liposome was loaded with a triple fusion plasmid of monomeric red fluorescence
protein, renilla luciferase, and herpes simplex virus truncated thymidine kinase or DOX. In addition,
an anti-CD44 antibody was conjugated to the loaded liposome [84]. Unlike liposomes which have
lipid bilayer, micelles are a lipid monolayers. Abdelmoneem et al. utilized dual-functionalized
spray-dried casein micelles (CAS-MCs) for combined delivery of two phytochemicals; berberine (BRB)
and diosmin [85]. Bogorad et al. studied lipidoids, which are lipid-like molecules that are synthesized
from alkyl-amines and alkyl-acrylates to deliver siRNAs that knockdown all integrin subunits in
hepatocytes [86]. Besides liposomes and micelles, groups have also applied lipid NPs to deliver
bioactive factors. As an example, Xu et al. utilized targeted solid lipid NPs to deliver docetaxel.
The primary components of this NP were dioleoylphosphatidyl ethanolamine (DOPE) and egg yolk
phosphatidylcholine (ePC), which are both biodegradable and biocompatible [87]. Huang et al. also
investigated lipid NPs; however, their NPs consisted of 1,2-distearoyl-sn-glycero-3-phosphatidylcholine
(DSPC), 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000
(DMPE-PEG2000), cholesterol, and a cationic lipid (RL01) and they were aimed to deliver anti-miR-17.
Lipid-based NP ability to easily and spontaneously self-assemble in aqueous environments, from
chemical components/monomers that are designed optimally, into vast three-dimensional particles
make it promising vehicles for drug delivery.
4.1.6. Other Particles
There are many other types of particles that have been developed using diverse biomaterials to
be applied in the treatment of HCC. Among those, Wang et al. used hydroxyapatite NPs to delivery
selenium [88]. Hydroxyapatite material itself is able to induce cell death and, thus these NPs act as both
a drug delivery vehicle and anticancer agent for HCC [89,90]. Pullulan-based NPs were investigated
by both Zhang et al. [57] and Wang et al. [91]. Pullulan is a polysaccharide enabling advantages
as it exhibited pH-sensitive properties, thus allowing control release property. There are several
other materials that have been used for liver cancer therapy including lipid-coated calcium carbonate
NPs [92], galactosamine-conjugated albumin [93], polyisohexylcyanoacrylate [94], dendrimer NPs [95],
insulin multimethacrylate particles [96], and glass microspheres [97].
4.2. Local Delivery
Compared to systemic delivery, local delivery of therapeutics allows for the decrease of systemic
toxicity and increase bioavailability of the drug. By delivering drugs locally, the drug concentration at
the tumor environment can be maximize and non-target systemic exposure and organ toxicity can be
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minimized. Furthermore, local delivery can increase the efficacy of the drug by bypassing the harsh
environment and longer journey that the drug has to take to reach the targeted site of interest.
4.3. Local Implantation
Che et al. used PCL electrospun nanofibers to deliver both a drug (i.e., PTX) and gene (i.e.,
miRNA-145) [98]. They showed that the implantation of these biomaterials in the liver after tumor
removal significantly decreased the recurrence and improve the overall survival in patients with HCC.
Radiotherapy can be often used as adjuvant therapy for the prevention of the recurrence of cancer
and/or metastasis after the surgical resection of the tumor. Wang et al. implanted non-degradable glass
microparticles to deliver phosphorus-32 for preventive regional radiotherapy after hepatectomy [97].
An absorbable gelatin sponge soaked with the microparticle suspension was buried within the resection
surface. This implant was able to significantly decrease the recurrence of HCC after tumor resection.
There are several groups that have looked at developing ‘polymer millirods’ that can be implanted in
the tumor. Weinberg et al. [99,100] and Qian et al. [101] developed DOX-containing PDLLGA cylindrical
polymer millirods (length 8 mm, diameter 1.5 mm). Thus, Weinberg et al. demonstrated that these
DOX-containing implants were able to provide high DOX concentration at the tumor site, resulting
in significant decrease in tumor size compared to the untreated control (Figure 8) [99]. These PLGA
millirods have also been used to deliver other chemotherapy drugs such as carboplatin [102] and
5-fluorouracil [103].
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Hanes et al. injected gelatin and chondroitin sulfate microspheres loaded with IL-2 near the
tumor site. Microsphere degradation was mediated by tumor expression of degradative enzymes
like collagenase, leading to the local delivery of interleukin-2 [104]. HCC receives a majority of
their blood supply from the hepatic artery compared to the portal vein for normal liver. In TACE,
a catheter is placed in the branches of the hepatic artery and chemotherapy agents can be infused
into the artery [105]. Drug eluting beads (DEB) is often used in combination with TACE to deliver
chemotherapy into adjacent tissue [106,107]. These DEBs are usually made of polyvinyl alc hol (PVA)
hydrogel that has be n sulphonated to enable the binding of chemotherapy drugs. Hong et al. u ilized
sulfonate-modified PVA hydrogel DEBs to delivery DOX which was administered intra-arterially
in the same exact mann r as wi h TACE [108]. Pawlik et al. applied DOX-DEBs and soraf nib in a
Phase II trial [109]. They demonstrated that these combination in u re ectable HCC pati nts were
well tolerated and toxicity can be managed with Sor dose adjustment. Besides DEB, microparticles
made of PLGA have also been used in combination with TACE. Qian et al. used TACE with mitomycin
C-loaded PLGA microparticles [110].
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5. Biomaterials for Bioactive Factor Delivery in Liver Cancer Therapy and Imaging
5.1. Chemotherapy
DOX, also known by one of its trade name Adriamycin, is one of the most common drugs used
in liver cancer therapy and in many biomaterial based therapies [58,65,77,79,82,83,93,96,108,109,111].
Besides DOX, taxel-based drugs, such as docetaxel and PTX, are often used in biomaterial based therapies
for HCC as well [57,59,87,98]. Liang et al. studied PTX loaded poly(γ-glutamic acid)-poly(lactide)
NPs to deliver chemotherapy for HCC [59]. PTX is primarily utilized for breast and ovarian cancers,
however, as shown by Liang et al., it can also effective in treating HCC [112,113]. Zhang et al. also
used PTX, but in combination with combretastatin A4, which will be discussed later in this review.
Although it is structurally similar, docetaxel has shown to be more effective than PTX [114]. Docetaxel
functions as an inhibitor of the depolymerization of microtubules. Xu et al. loaded docetaxel into
the solid lipid NPs [58]. 5-Fluorouracil (5-FU) is a chemotherapeutic drug that disrupts nucleoside
metabolism resulting in DNA and RNA disorders [115,116]. Ma et al. utilized this drug by conjugating
it to PLA NPs [56]. Tomuleasa et al. tested multiple different chemotherapeutic drugs by loading gold
NPs with cisplatin, capecitabine, and DOX.
5.2. Radiotherapy
Radiotherapy can be often used as adjuvant therapy for the prevention of the recurrence of cancer
and/or metastases after the surgical resection of the tumor. Wang et al. investigated non-degradable
glass microparticles to deliver phosphorus-32 for preventive regional radiotherapy [97]. As it decays,
this radioisotope emits high energy beta particles. Wang et al. demonstrated that the glass microspheres
implanted in the liver was able to significantly decrease recurrence after surgery.
5.3. Immunotherapy
Immunotherapy is a promising approach for cancer treatment as it has the ability to develop
long-term immunity to the tumor originally treated [117]. Microparticle systems have shown ability
to improve immune response. As an example, Hanes et al. used gelatin and chondroitin-6-sulfate
microspheres to deliver IL-2 for immunotherapy [66]. Previously, IL-2 has been used to treat melanomas
and renal cell carcinoma through systemic means, but it has shown to be toxic in high doses [118].
Genetically-engineered autologous cells are currently the gold standard for immunotherapy [118].
These particles developed by Hanes et al. are relatively easier to manufacture compared to these
cells, and thus present a promising approach for cancer immunotherapy. Ma et al. used SM5-1,
a monoclonal antibody, as immunotherapy because it binds to p230, a membrane protein overexpressed
in HCC [78]. This antibody was shown to impede tumor growth, induce apoptosis, and downregulate
tumor angiogenesis [73,119–121].
5.4. Natural Occurring Compounds
Natural occurring compounds are drugs that can be extracted from plants and animals.
Abdelmoneed delivered two phytochemicals extracted from plants; berberine (BRB) and diosmin (DSN)
using micelles [85]. Ni et al. delivered both curcumin- and 5-fluorouracil-loaded with biotin-/lactobionic
acid–modified PEG-PLGA-PEG (BLPP) copolymer NPs and saw synergistic anticancer effects (i.e.,
cytotoxicity) in vivo [60]. Curcumin is a polyphenol extracted from turmeric inducing anti-angiogenic,
antitumor, and anti-inflammatory physiological responses [122]. Bu et al. also focused on a naturally
occurring compound. They loaded trans-resveratrol (as a model drug), a natural plant compound,
into CNPs, demonstrating that NPs were more effective on cancer cells compared to trans-resveratrol
solution [69].
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5.5. Gene Therapy
Gene therapy is used to treat a disease by transferring a therapeutic nucleic acid (i.e., plasmid
DNA, siRNA, or microRNA) to introduce a new gene or restore, increase or halt gene expression of
a gene.
5.5.1. Plasmid DNA
Plasmid DNAs are double-stranded, closed, and circular vectors often used for gene delivery
due to recombination techniques that allow genes to be inserted into the plasmid. Xue et al. utilized
galactosylated-carboxymethyl chitosan-magnetic iron oxide (Gal-CMCS-Fe3O4) to deliver the tumor
suppressor gene Ras Association Domain Family 1A (RASSF1A) [72], which plays a vital role in
apoptosis, cell-cycle regulation, and microtubule stability [123,124]. HCC are lacking RASSF1A
expression [125] and thus, the delivery of this plasmid in combination with intraperitoneal injection
of mitomycin and an external magnetic field resulted in smallest tumors compared to other groups
tested. The re-expression of the RASSF1A gene resulted in increased sensitivity of HCC cells to
the chemotherapy drug mitomycin [72]. Xu et al. also combined chemotherapy with gene delivery.
They designed a double layered microparticles loaded with the chemotherapy drug DOX in the core
and chitosan-DNA NPs containing the gene encoding the p53 tumor suppressor protein (chi-p53) in the
shell. The combined treatment with DOX and chi-p53 treatment demonstrated enhanced cytotoxicity
as compared to either DOX or chi-p53 treatments alone. The p53 gene is a gene that is often mutated in
HCC, mostly in the apoptosis pathway mediated by p53 [126]. Thus, p53 expression using plasmid
DNA could help fix the control of normal cell growth.
5.5.2. siRNAs
Small interfering RNAs (siRNAs) are noncoding sequences used to disrupt the effects of mRNAs.
Gao et al. combined the delivery of a chemotherapy agent, Adriamycin, and ribonucleotide reductase
M2 (RRM2) siRNA with liposome-polycation-DNA complex (LPD) conjugated with anti-EGFR
(epidermal growth factor receptor) [127]. RRM2 expression is higher in HCC than in non-HCC tissue
and thus RRM2 siRNA is a promising therapy for HCC. Adriamycin may induce upregulation of
RRM2 and thus, the combination of Adriamycin and RRM2 siRNA can result in combined therapeutic
effects. The combined therapy resulted in enhanced therapeutic effects (i.e., cytotoxicity, apoptosis, and
senescence-inducing activity) compared with single-drug loaded or non-targeted controls. Bogorad et al.
delivered siRNAs targeting all integrin subunits in hepatocytes [86]. Integrins play an important role
during development, regulating cell differentiation, proliferation, and survival. The knockdown of the
integrin receptors significantly retarded the progression of HCC.
5.5.3. miRNAs
MiRNAs are also noncoding RNAs that are around 22 nucleotide long that modulate mRNA
stability and expression. MiRNAs can target multiple mRNAs simultaneously, while siRNAs can target
only one at a time [128]. Zhou et al. studied the delivery of the let-7g tumor suppressor miRNA using
dendrimer NPs that mediate miRNA delivery to late-stage liver tumors with low hepatotoxicity [95].
Huang et al. delivered antimiR-17 with a lipid NP. MiR-17 is an oncogene, and ectopic expression with
miR-17-3p results in the development of HCC in a mouse model [129,130]. The suppression of this
oncogene through antimiR-17 delivery hindered the proliferation of HCC cells. Although a first-line
drug for HCC, Sor often induces resistance due to autophagy [92]. Thus, Zhao et al. investigated the
delivery of Sor in combination with miR-375, an inhibitor of autophagy with lipid-coated calcium
carbonate NPs. Xue et al. also delivered miR-375, but using gold NPs [75]. Finally, Che et al. delivered
miRNA-145 in combination with PTX from an electrospun PCL scaffold [123].
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5.6. Imaging
Imaging in cancer therapy is vital to assess tumor growth and/or ensure and track the delivery of
treatments. Wang et al. applied liposomes to deliver a reporter system imaging agent which allowed
them to monitor and evaluate the efficiency of targeting the tumor [84]. The triple fusion (TF) plasmid,
consist of monomeric red fluorescence protein (RFP), renilla luciferase (Rluc), and herpes simplex virus
truncated thymidine kinase (HSV-ttk) reporter genes and was used to monitor the response of the
tumor to DOX delivered using the same liposome system. Bio-optical bioluminescence imaging (BLI)
was used to monitor tumor growth status by Fluc and targeting of the liposomal particles to the site by
Rluc (Figure 9).
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Figure 9. Schematic of targeted liposomes for imaging and therapy of HCC. The HCC model was
developed by in situ injection of DF (Fluc, GFP) HepG2 cells with the progression or regression of HCC
bearing tracked by Fluc imaging in vivo. The targeting of CD44 conjugated liposomes can be tracked
by Rluc imaging. HCC regression resulted from administration of GCV and DOX. Reprinted with
permission from Elsevier, Wang et al., Biomaterials, 2012 [84].
Besides being used as drug delivery vehicles, ultrasmall superparamagnetic iron oxide can be
employed as contract agent in MRI. Indeed, Kou et al. utilized these particles for diagnostic imaging of
HCC [73].
6. Targeted Delivery
Syst mic delivery systems often result in the accumulation of drugs in the mononuclear phagocytic
system cells in the liver, spleen, and bone marrow [131], and increase in hematologic toxicities due to
circulation time [132]. Targeting agents to tumor cell surface antigens or receptors allow biomaterials
to effectively and efficiently deliver bioactive factors to the cells of interest while decreasing side effects
to non-targeted cells.
6.1. Antibodies
Antibodies have evolved into tumor targeting agents for drug delivery. Gao et al. used NPs
conjugated with anti-epidermal growth factor receptor (EGFR) since HCC cells overexpress EGFR [127].
They found that the NPs can be efficiently delivered to EGFR-overexpressing or moderately-expressing
HCC cells, but not to the HCC cells with low levels of EGFR. Wang et al. selected anti-CD147 antibodies
to target HCC cells [83]. CD147 is an important marker in the progression of HCC and thus, it is also
highly expressed on the surface of HCC cells. Due to the EPR effect, the liposomes aggregated on the
tumor and then absorbed through ligand mediated internalization. Wang et al. used anti-CD44 as a
targeting agent to target cancer stem cells (CSCs) for HCC therapies [84]. Ma et al. employed SM5-1,
a humanized mouse antibody that has a high binding affinity for a membrane protein, p230, a 230
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kDA membrane protein overexpressed in HCC cells, in PLA NPs [56]. Ma et al. also used gold NPs
conjugated with SM5-1. This antibody was also used by Kou et al. with ultrasmall superparamagnetic
iron oxide for diagnostic imaging. Besides being a targeting agent, SM5-1 has been proved to be able
to inhibit tumor cell growth or induce apoptosis [78].
6.2. Carbohydrate-Targeting Agents
Due to the prevalence of carbohydrate-binding receptors on hepatocytes, carbohydrate can also be
used as targeting agents for HCC. Xue et al. delivered RASSF1A gene using a dual targeting approach
through galactosylated-carboxymethyl chitosan-magnetic iron oxide NPs (Gal-CMCS-Fe3O4-NPs) [133].
The galactosylation targets the asialoglycoprotein receptors (ASGP-Rs), while an external magnetic
field improves the efficiency of the gene therapy, potentially by directing the NPs to the target site [20].
ASGP-Rs are highly expressed on HCC cells. Xu et al. also used a galactose moiety in the form of
galactosylated DOPE, which was conjugated using lactobionic acid, to target the HCC cells. The uptake
into the cell was controlled by ligand-receptor binding, and endocytosis was mediated by clathrin.
Liu et al. covalently conjugated a hydrophilic glucosyl-galactose disaccharide, lactose, to DOX in order
to target the ASGPRs [65]. Wei et al. investigated Lactoferrin (Lf) to target HCC cells as Lf is able
to bind to the ASGP-R as well [134,135]. Galactosamine is another target for the ASGP-R. Shen et al.
conjugated this target to albumin NPs and used it to delivery DOX [93,111]. Similarly, Liang et al.
delivered PTX using poly(γ-glutamic acid) and poly(lactide) NPs with galactosamine conjugation to
target the liver cancer cells which resulted in specific interaction with the hepatoma tumor in mice via
ligand-receptor binding. This targeted chemotherapy demonstrated enhanced reduction of the tumor
in comparison to the non-targeted NP-PTX therapy [59]. Zhang et al. [57] targeted the ASGP-Rs as
well. The pullulan polysaccharide backbone in their biomaterials bind naturally to ASGP-Rs as shown
in Figure 5 [136]. Ni et al. used a dual targeting approach to target HCC cells [60]. Poly(ethylene
glycol)-poly(lactic-co-glycolic acid)-poly(ethylene glycol) (BLPP) copolymer NPs were synthesized and
conjugated with biotin-/lactobionic acid for targeted delivery of curcumin- and 5-fluorouracil. Due to
the dual targeting, a higher cellular uptake was seen in HCC cells, and a lower residual accumulation
was seen in normal tissue in comparison to the single targeting and non-targeting NPs [60]. Similarly,
Abdelmoneem et al. used lactobionic acid and folic acid to target nanomicelles loaded with the
phytochemicals berberine (BRB) and diosmin (DSN) to HCC cells [85].
6.3. Peptide/Protein-Targeting Agents
Monoclonal antibody have shown clinical potential, however its associated with impaired tumor
penetration [82]. Therefore, peptide-targeting agents have been developed to overcome this. Lo et al.
identified SP94, as a peptide targeting agent specific for HCC [82]. This peptide was conjugated to
PEGylated liposome and used to deliver DOX. The peptide-targeting agent can decrease hematologic
toxicities by avoiding the reduction in the total WBCs. When administered in vivo, there was
significantly more SP94 accumulated at tumor sites than other organs. Bibby et al. delivered DOX with
a NPs with a core made out of insulin multi-methacrylate with a targeting peptide, cyclic RGD [96].
6.4. Enhanced Permeability and Retention Effect (EPR)
Several biomaterials themselves often result in the selective accumulation of these vehicles and
their payload into tumors instead of normal tissue due to the enhanced permeability and retention effect
(EPR) [137]. CNPs are a prime example of this [67,68]. Particle size plays a role in the accumulation of
particles in the liver. Smaller particles are more likely to be internalized and aggregate at the tumors
due to the enhanced permeability and retention effect (EPR) [138]. However, larger NPs (>200 nm)
are more likely to be recognized by monocytes and the reticuloendothelial system [139]. Particles
made with gold also acts as its own targeting agent for HCC as gold accumulates in the liver [75].
Tomuleasa et al. [77], Paino et al. [74], and Ma et al. [78] did not use gold as only the bioactive factor,
but also as the targeting agent. Instead of using the biomaterial as the targeting agent, Ma et al. also
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conjugated the gold NP with SM5-1, which targets an overexpressed surface protein, p30 in HCC [78].
Zhou et al. also demonstrated that their dendrimers NPs localize to liver site, not depending on a
specific targeting agent [95]. However, the cell type-specific uptake and intracellular release depended
on chemical structure of the different dendrimers.
7. Biomaterial-Based 3D In Vitro Models to Study Liver Cancer
7.1. 2D Versus 3D Cellular Models for HCC
In recent years, the increased development of biomimetic scaffolds for various biological
applications has shown that the behavior of cells in three dimensional (3D) is very different from that
of the same cells in bidimensional (2D) structures [140]. The remarkable effect played by the third
dimension over cell growth has been observed in smaller and simpler cellular aggregates, such as
spheroids, up to more architecturally complex biomaterial-based porous scaffolds [141]. Both the
cellular genotype and phenotype, as well as the various biological phenomena (e.g., proliferation,
differentiation, function), have been found to greatly differ in the two culture methods. These diversities
can be even more evident when comparing the two models according to cancerous cells. As an example,
several studies have shown that the 3D culture of tumor cells leads to a worsening of the malignant
phenotype and an increase in drug resistance if compared to 2D culture, thus suggesting that 3D
models reflect the phenomenology of in vivo tumors much more faithfully [142,143] (Figure 10).
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From an historic perspective, the first studies related to the development of 3D in vitro models for
liver aimed to create structures for tissue engineering and organ transplantation [144]. Subsequently,
these models were also used for the evaluation of the efficacy and cytotoxicity of drugs, as well as
for the study of cell metabolism and pathological phenomena. Initially, the cells grown on these
3D supports were primary hepatocytes from rat or, most rarely, isolated from a patient. Indeed,
the difficulty in isolating human cells and the poor survival capacity of primary liver cells in culture
have led researchers to use cell lines derived from hepatocellular carcinoma (HCC), such as HepG2,
HepaRG, Huh7, and others [145]. The behavior of these lines appeared to be very similar to that
of primary cells with respect to the morphological aspect (e.g., cellular polarity), the synthesis of
molecules such as albumin and urea, the activity of detoxification enzymes, and the formation of
similar structures in the biliary canaliculi. Moreover, the 3D culture of these cell lines in the form
of spheroids has also been applied in researches aimed to obtain more detailed information on the
molecular mechanisms of liver tumor development and for the evaluation of the pharmacological
response to new anticancer drugs [144]. More recently, spheroids have evolved into organoids, which
are obtained by inducing the aggregation of multiple cell types (e.g., endothelial, mesenchymal, hepatic)
into macroscale (millimeter size) constructs acting as functional units [146]. Organoids have also been
derived from liver cancers [147]. However, due to their compactness, these organoids are usually vital
only for a limited timeframe in vitro. To have longer usable time points, scientists therefore use to
disaggregate and reform the organoids over time, like cells in culture.
The great advantage of biomaterial-based scaffolds over spheroids and organoids is multifold:
(1) allows for a better tissue biomimicry by providing a preliminary artificial extracellular matrix (ECM)
on which the cells can grow and assemble in a natural fashion, (2) provides mechanical and architectural
cues to which the cells can respond with a more reliable function, (3) can impart chemical signals thanks
to the chosen biomaterial and/or biomolecules, (4) permits cell survival for long times thanks to its
porosity, and (5) enables the generation of complex multicellular constructs in which diffusion gradients
can be consistent to cell viability and function [142]. For the development of 3D culture models of
HCC, both natural and synthetic materials have been used to obtain biodegradable and biocompatible
scaffolds with a porosity suitable for cell proliferation and microvasculature formation and infiltration.
The first scaffolds used in this research area have been produced starting from the (co)polymers
approved by FDA for biomedical applications, namely, polyglycolic acid (PGA), PLLA, PLGA, PCL,
and some others [148,149]. These biomaterials were processed into porous scaffolds prepared via
different techniques, including rapid prototyping and solvent evaporation combined with particle
elimination and cultured with hepatocytes for liver regeneration [150]. Only more than a decade later,
the concept of tissue engineering, which is inherently based on the use of biomaterial-scaffolds, has
been transferred to cancer research [151–154].
7.2. Hydrogel-Aided Spheroids for HCC
Spheroids are artefacts obtained in cell culture leading to compact cellular microspheres with a
broad size range (20–1000 µm) which have become largely used in cancer research [142,155]. In order
to improve the reliability of the results obtained with the spheroid model, many 3D cultures of liver
tumor cells are availing themselves of hydrogels based on collagen, alginate or gelatin, containing
molecules or growth factors immobilized in the structure via different chemical processes, even though
also synthetic hydrogels are recently gaining attention for their peculiar properties, such as stimuli
responsiveness [143,156–161]. Within these hydrogel structures, spheroidal masses or cell aggregates
are formed under non-adherence conditions, in which the ECM-cell interactions are very narrow and
grant for a better communication of intracellular transduction signals. Inherently, spheroids can only
partially mimic the tumor microenvironment (TME) in terms of ECM secretion, interaction between
cancer cells, diffusion gradients therefore increased resistance to treatments, whereas they lack of other
TME features, including phenotype diversity and tissue architecture [155,162]. Moreover, difficulties
in controlling spheroid size and obtaining consistent outcomes from assays have been reported,
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therefore many efforts are being reported on the standardization of spheroid size and function [163,164].
Spheroids thus represent a primary model of 3D cell culture, which for its simplicity can still contribute
to cancer investigations and can give preliminary insight on 3D phenomena [155,162,163].
There are several works reporting on hepatic cells that better express their function in spheroid
culture, and different synthetic hydrogels have been used to better control shape, size and formation
of spheroids due to their stimuli-responsiveness to specific external triggers, therefore reacting to
dynamic microenvironments [159,160]. For example, a redox responsive hydrogel based on PEG
allowed increased liver-related functionalities, in terms of albumin and urea synthesis, in spheroids of
the hepatoma cell line HepG2 [159]. A covalent disulfide hydrogel network based on a star-branched
PEG derivative (8-arm PEG-SH) served for the formation of HepG2 cell spheroids. Cell recovery was
also possible thanks to the polymer biodegradation under mild reducing conditions exerted by cysteine
(Figure 11).
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Figure 11. (A) Fabrication of a redox-degradable hydrogel by using horseradish peroxidase (HRP)
catalysis: self-oxidation of a thiolated polymer generating hydrogen peroxide, hydrogelation (dashed
arrows), HRP-mediated phenoxyradical formation promoting disulfide bond between the thiolated
polymers (solid arrows). (B) Schematic of the fabrication and the recovery of cellular spheroids using
redox-responsive hydrogels: encapsulation of target cells, spheroid formation by cell proliferation,
recovery of the spheroids by degrading the scaffolds under reductive conditions. Reprinted with
permission from Wiley, Moriyama et al., Biotechnol. J., 2016 [159].
Another study has reported on the use of a temperature responsive hydrogel based on
poly(N-isopropylacrylamide) (pNIPAAm)-co-gelatin for spheroid formation, in which the hepatoma
cell line Hepa/8F5 derived from a genetically engineered mouse model showed higher function with
respect to the 2D cell counterpart, according to albumin synthesis and other metabolic activities [160].
In addition, Hepa/8F5 cell spheroids grown in presence of pNIPAAm after doxycycline induction
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become drug-resistant, not only to tamoxifen but also to acetaminophen. This cytotoxicity study,
among others, pointed out the protective role of 3D cell aggregation as a diffusion barrier to toxic
molecules [155,160,164,165]. The tight cellular 3D aggregation in spheroids brings both positive and
negative effects: on one hand, cells show improved secretive and metabolic functions; on the other
hand, the diffusional limitations inhibit molecular trafficking, which in turn has consequences on the
spheroid vitality [164].
The phenomena of cellular necrosis due to hypoxia in spheroids in some cases has been considered
a limiting factor for the use of hydrogels. However, hypoxia-induced cell death has been found in
the in vivo tumor environment in which the cells are deprived of oxygen and modify their behavior
by developing a more aggressive phenotype [166]. In an instructive study, some researchers have
developed a 3D model based on a collagen hydrogel. Co-cultures of HepG2 cells and stromal fibroblasts
have been used to obtain hetero-spheroids, namely, spheroids formed by both tumor cells and stromal
cells, of uniform and controlled size [161]. Subsequently, these were encapsulated in a collagen hydrogel
to create a 3D model of HCC also used for the evaluation of the anti-tumor drug response to DOX. The
results of this study have shown that the formation of hetero-spheroids is able to mimic some features
of the in vivo TME, in which viable, proliferating, and functionally active cells, as demonstrated by
cytochrome P450 activity, were observed.
DOX treatment showed higher chemoresistance in hetero-spheroids than in 2D culture conditions.
This phenomenon seems to be related to the compactness of the spheroid structure, in which the cells
layering on the outer surface would act as a barrier by hampering the penetration of the drug in the
innermost layers, and to the hypoxic area at the central level of the spheroid, which would modulate
the response of the cells by enhancing their endurance and vitality [155,160,161,164,165]. The increased
resistance to the DOX action has also been attributed to the presence of collagen encapsulating the
spheroids, as a further physical barrier to drug diffusion which at the same time better supports cell
vitality and proliferation thanks to cell-ECM interactions [161,164].
Xu and collaborators have used alginate hydrogels to evaluate in detail the possible cellular and
molecular mechanisms that preside over the development of HCC metastases [143]. Alginate is a
polysaccharide derived from brown algae which is widely used for its simplicity to obtain biocompatible
hydrogels [167]. The structure of these gels is obtained by ionic crosslinking with bivalent cations,
such as Ca2+, in order to control their mechanical properties and enable a better recovery of the
spheroids [168]. In the study reported by Xu et al., two HCC cell lines, one with low metastatic
potential (MHCC97L), the other with high infiltrating capacity (HCCLM3), were encapsulated in
alginate spheres. The results highlighted that the cells grown in the spheroids reached an increased
maturity in the 3D culture with respect to the monolayers. This increase was even more evident in
the cells retaining high metastatic potential, thus suggesting that this alginate hydrogel is able to
structurally and functionally mimic the hepatic TME [143] (Figure 10). Indeed, it has been largely
reported that alginate is a valid biomaterial for long term hepatocyte cultures, including HepG2
cells [156,169]. Alginate can easily incorporate biological molecules to better mimic the liver TME
(Figure 12). Sun et al. developed decellularized liver ECM-alginate hybrid gel beads for HCCLM3 cell
culture by using a simple setup, demonstrating increased cell viability over time as a model of study for
liver cancer metastasis [170]. Concerning the dimensional control of the spheroids, Lau and coworkers
have indicated that alginate hydrogels can serve for entrapping gelatin microspheres so as to embed
HepG2 cells in a large amount [157]. After encapsulation in the hydrogel, the genipin cross-linked
microspheres were dissolved using metalloproteinase-9 (MMP-9) to create cavities with a predefined
diameter, not exceeding 200 µm, in which the cells could form small-sized spheroid aggregates. In
this way, the problem of formation of necrosis areas within the spheroidal masses due to the limits of
nutrient diffusion was better overcome [157,164]. Being a polysaccharide, alginate can be easily mixed
with other natural-origin hydro soluble biopolymers. Leung et al. have used alginate blended with
chitosan, a natural polysaccharide derived from the partial deacetylation of chitin, known to share
some structural similarities with the glycosaminoglycans present in the ECM [158].
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The use of this biomaterial combination allowed a porous and interconnected 3D structure to be
created, in which the characteristics of biocompatibility, biodegradation, non-immunogenicity, and
ability to stimulate cell differentiation were contemporaneously achieved. In particular, this study
aimed to carry out a pharmacological screening by cultivating two cell lines, HepG2 and PLC/PRF/5,
both on the chitosan-alginate scaffolds and 2D Matrigel®, the latter being gelatinous protein mixture
secreted by mouse sarcoma cells commonly used in cancer laboratory research [171]. The findings
reported by these authors have highlighted the ability of this 3D models to stimulate the formation of
cell aggregates with an increased expression of molecules related to tumor malignancy and ability
to metastasize. The obtained data also in this case confirmed that the 3D models enhanced cell
insusceptibility towards the chemotherapeutic drugs [158,161]. Furthermore, it was shown that the
cell-hydrogel complex implanted in the animal was able to induce a strong vascularization [158].
All the above-mentioned studies reporting on HCC spheroids obtained using hydrogels
documented the improved ability of these 3D structures in recapitulating functional and chemoresistance
traits of HCC, which is poorly found if the same cells are cultured in 2D. From this point of view,
spheroids represent an easy and valuable model for HCC drug screening [158,160,161,172]. Collectively,
these findings also highlighted the key role played by biomaterials, synthetic, biological, and bioartificial
hydrogels in facilitating spheroid formation, size control, and cell recovery, in addition to enhancing
cell–cell and cell–matrix interactions, which in the end catalyze a more reliable cell function and drug
susceptibility. In some cases, cell necrosis, frequently observable in spheroid models, can replicate
pathological aspects and therefore be still useful in cancer research. However, the intrinsic nature of
spheroids as artificially aggregated cell clusters is revealed by lack of morphological similarity with
the native tumor, which in the end hampers more sophisticated observations to be taken from this
3D model.
7.3. Biomaterial-Based Scaffolds for HCC
The concept of cancer tissue engineering has only recently come to a diffuse scientific interest,
but has attracted great attention [142,151–154]. Biomaterials-based supports endorsing the concept of
tissue engineering, which relies on porous scaffolds acting as a preliminary synthetic ECM, can be
exploited to better comprehend 3D cell behavior [173]. Conversely from spheroids, in these artificial
microenvironments provided with porosity and topographical and mechanical cues, cells can find
their own 3D organization and hierarchical structure. The scaffolds can be provided with different
architectures by tissue-engineers—e.g., spongy or fibrous, smooth or nanopatterned—thus resembling
specific traits of a tissue of interest [149,173]. Multiple cell populations can also be seeded on these
structures, with clinically relevant dimensions (e.g., 5–8 mm size), to reach even complex macroscopic
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3D models [174]. Starting from early regenerative goals in the eighties, in recent years tissue engineering
has been evolving also towards in vitro tissue disease modeling, including cancer [142]. Only a few
review papers on cancer tissue engineering can be found before 2010, thus confirming the novelty
of this research field [152,153]. 3D scaffolds serve as an artificially created ECM able to provide a
preliminary structure for cell organization and growth, which can be highly instructive for the study of
cancer TME [142,151,153]. Indeed, both natural and synthetic origin scaffolds, provided with proper
physico-chemical, architectural, and mechanical features can provide biomimetic cues for tumor cell
growth [152,154]. Specifically, only a limited number of scaffold types have been reported, which can
give a preliminary insight on the role played by different biomaterials, mechanical properties and
structural architectures on HCC cell behavior, including, synthetic, biologic, composite (intended as
multiphase) and bioartificial (intended as synthetic and biologic blends of copolymers) [172,175–181].
As a first example, in 2007, Bokhari and collaborators have developed a 3D porous scaffold based
on polystyrene to culture HepG2 cells [172]. These authors employed a synthetic scaffold previously
developed for osteoblast growth, fabricated via high internal phase emulsion (HIPE) polymerization,
which is known as PolyHIPE Polymer (PHP). In this type of scaffold, in which the pore size and the
porosity can be tuned by changing the chemical composition of the emulsion and the processing
conditions, thus achieving maximum values of a few hundred microns and 97%, respectively [172,182].
The morphological evaluation of the HepG2/PHP constructs showed that the cells were viable, in the
proliferative phase, and were organized in aggregates enabling the formation of bile ducts rarely
observable in 2D cultures. Moreover, it was observed that the function of the cells grown on the
porous matrix was increased if compared to the monolayer culture, whereas, the 3D culture was less
susceptible to treatment with methotrexate, a hepatotoxic drug [172]. Many authors have pointed out
the need to investigate more in-depth the TME and the interactions of tumor cells with TME, in order
to clarify the molecular mechanisms underlying tumor proliferation and metastasis, with particular
emphasis to liver cancer [183].
Using the sol–gel method and leachable sucrose particles, Kataoka et al. proposed an
organic–inorganic scaffold constituted of tetraethoxysilane (TEOS) and polydimethylsiloxane
(PDMS) [176]. The authors indeed used commercial PVA scaffolds (from Able Co., Tokyo, Japan)
with pore size (130 µm and 200 µm) and porosity (about 90%) similar to those of their own scaffolds.
In TEOS–PDMS scaffolds, the HepG2 cells showed enhanced proliferation and clustering capacity with
respect to PVA scaffolds, which the authors attributed to the poral properties of PVA (e.g., smooth
pore surface and reduced size of interpore openings), supposed to impair an efficient cell clustering
in dynamic flow conditions as a consequence of the higher upstream static pressure under constant
flow, if compared to TEOS–PDMS scaffolds. As a result of 3D cultures, albumin secretion in was about
3-fold higher than in 2D cultures and independent of the scaffold polymer [176].
Among natural origin scaffolds used for liver cancer, Kundu and collaborators have reported
on silk fibers chosen for the mechanical characteristics of the material and the properties of fibroin,
a biocompatible silk protein, to naturally express the amino acid residues Arg-Gly-Asp (RGD),
as signaling molecules [177]. This amino acid sequence is present in the native extracellular collagen
and the cells are naturally able to bind it by surface integrins, showing improved viability [184]. These
scaffolds showed pores distributed in a range of 40–130 µm, values considered standard for nutrient
diffusion and cell infiltration. A particular HCC cell line was cultivated on this 3D substrate, HepR21,
which expresses at high levels the hyaluronic acid binding protein 1 (HABP1), a protein recognized
to be involved in the progression of the tumor and in the regulation of the metabolism of the tumor
cell [177]. The HepR21 cells also express high levels of hyaluronan, a component of ECM typical
of TME, which enables the formation of an extracellular reticulum, thus promoting cancerous cell
proliferation and metastasis [185]. The results of this study have proved that the HepR21 cells were
capable of adapting to the 3D support, forming aggregates evenly distributed in the scaffold and
showing a proliferative capacity and infiltration higher than the control cells (HepG2) cultivated under
the same conditions. Furthermore, the culture of these cells morphologically and functionally reflected
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the long-term culture characteristics of solid tumors in vivo [177]. Silk fibroin was blended with
chitosan, frozen and lyophilized to obtain silk fibroin/chitosan scaffolds apt for HepG2 cell growth [181].
In this system, the final porosity and mechanical properties of the scaffolds can be tuned by varying
the blend composition, thus leading to scaffolds with porosity > 95% and pores with size within
100–150 µm, if the concentration of biopolymers in the mixture is < 6% w/w. Even if this study of She
and colleagues was driven by a regenerative purpose, it was shown that HepG2 cells can intensively
proliferate in these 3D matrices, thus suggesting novel uses for their application. In another study
still aiming at liver tissue engineering, Gotoh and coworkers used silk fibroin conjugated with lactose
to obtain Lac-CY-SF sponges able to target β-galactose residues, which represent hepatocyte-specific
ligands [175]. These sponges displayed pores with variegated shape and size: round (100 µm) and
elongated (250–450 long and 100–150 µm wide). The authors compared the function of FLC-4 cells
cultured in Lac-CY-SF, plain silk fibroin and collagen sponges for 3 weeks. Interestingly, the transferrin
and HNF-4α genes were only expressed by cells cultured in Lac-CY-SF sponges. These results highlight
the specific responsiveness of cells to different biomaterial substrate and corroborate the potential of
silk as an instructive biopolymer for HCC modeling for its capability to be blended and conjugated
with other biomolecules [175,181]. In order to better mimic the liver tissue as a microenvironment
for hepatic cell growth, including HCC cells, decellularized liver appears as an interesting scaffold.
Mazza et al. were able to completely decellularize human liver with maintenance of the original
parenchymal architecture [179]. The acellular tissue was cut into 125 mm3 cubic scaffolds which were
seeded with hepatic stellate cells (LX2), hepatocellular carcinoma Sk-Hep-1 and HepG2. The cells,
cultured for 3 weeks, were vital, proliferative, and able to remodel the scaffold ECM.
The analysis of HCC TME using a tissue-engineered model has also been performed by Liang et al.,
who developed a new strategy to control the rigidity of a type of collagen hydrogel scaffold, and
minimize variations in gas permeability and the number of sites of accession [178]. In this study, a
gel was created by crosslinking collagen fibrils with various concentrations of a copolymer based on
PEG and succinic acid. The change in the mass ratio between the two polymers led to the formation of
hydrogels with variable elastic compression modules (E0) in the range 0.7–4.0 kPa. HepG2 cells were
embedded in these collagen-PEG supports and in pure collagen hydrogel by an on-site cross-linking
reaction. The results obtained highlighted that the tumor cells were able to form cellular aggregates
of different diameters and inversely proportional to the hydrogel rigidity. In fact, clusters with a
diameter ranging in 30–330 µm were observed in the supports in which the E0 value was 0.7 kPa
(corresponding to that of soft tissues such as fat), whereas clusters with a diameter within 20–60
µm were more represented in supports with an E0 value of 4 kPa (corresponding to that of healthy
liver) [186]. The cells of the spheroids obtained in the soft hydrogel had a proliferative and infiltration
potential much higher than those observed in the stiff hydrogel. In addition, the spheroids obtained in
soft hydrogel showed an increase in β1-integrin expression, by resulting in increased cell adhesion
to ECM, and VEGF, a factor responsible for the development of new vessels around the tumor [178].
The data obtained suggested that the rigidity of the scaffold was able to influence the phenotype and
activity of the encapsulated cells [187,188].
Among the hydrogels as 3D models of HCC have recently been studied are also those of PVA,
a synthetic polymer capable of physical cross-linking at low temperatures (i.e., cryo-gelation) by
forming lamellae that are consolidated through thermal cycles of freezing and thawing [180]. A suitable
hydrogel was obtained by adding gelatin in the PVA solution to obtain a PVA/gelatin 80/20 (w/w)
matrix with a final morphology that appeared similar to the liver parenchyma. By using bioartificial
PVA cryogels, mixed with diverse biomolecules at different weight ratios, it is possible to slightly
vary pore size distribution and scaffold inner morphology [189]. For PVA/gelatin blends, simple
freeze-thawing allowed the largest pore volume to be occupied by pores with size lower than that
obtained with emulsion and lyophilization [189–191]. Specifically, in the PVA/gelatin hydrogels
prepared by Moscato et al., 71.59% ± 5.03% of the measured volume was due to pores with diameters
ranging in 0.007–30 µm, while only 28.41% ± 4.57% of the measured volume derived from pores with
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diameters ranging in 30–150 µm [180]. Therefore, the pore size of these PVA/gelatin scaffolds greatly
differ from that of the commercial pure PVA scaffolds used by Kataoka et al., which in addition is
reported as non-distributed [176]. In PVA/gelatin hydrogels, proposed by the authors as scaffold
models for the study of HCC cell migration, HepG2 cells were cultured up to 24 days. A morphological
study highlighted the formation of macro-aggregates with cellular areas with different morphology.
In particular, at the endpoint, together with a significant increase in cellular metabolism, a forward-front
area was identified in which the cell-scaffold interactions appeared to promote the expression of
α5β1-integrin and β-actin. The strong immunolocalization of these proteins on the lateral edge of the
cell membrane placed on the forward-front, suggested the presence of lamellipodia apt for migration.
The cells present in the central area of the aggregate, however, they were organized similarly to those
found in HCC. The authors also reported an intermediate zone with signs of necrosis, unlike what
happens in the spheroids where the necrotic area is usually the central one. This area could play a
role in the secretion of factors that induce morphological changes in HepG2 cells in the forefront area
(Figure 13).
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Figure 13. Immunohistochemical analysis of HepG2 cells cultured in monolayers (a,b); samples of HCC
tumor (c,d) and HepG2 cells cultured inside PVA/G hydrogels (e,f). For each sample type, negative
controls (a,c,e) and β-actin expression (b,d,f) are shown. S1, S2 and S3 in (e,f) define the areas of
different morphotype localization within the cell/scaffold constructs. The insert in (f) shows a few
cells with a lamellipodial-like expression of β-actin, indicated with an arrow.MDPI Creative Common
Attribution license, Moscato et al., J. Funct. Biomater., 2015 [180].
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As the lower pore size in this scaffold if compared to all the other ones reported in this section
possibly reduced cell motility, a better observational window of migratory phenomena was made it
possible, which could be useful for further investigations related to HCC invasiveness and progression.
Table A2 summarizes the main findings per biomaterial, model (spheroid, bead, and tissue-engineered)
and cell type (Appendix B).
The studies on biomaterials and scaffold types for HCC modeling are limited and still variegated.
Up to now, the primary applications of tissue-engineered models rely on the generation of HCC
or normal liver tissue, and no drug screening has been performed yet. Differently from spheroids,
only in tissue-engineered constructs tissue-biomimetic cellular organization has been found [172,180].
Improved cell function can be generally observed in 3D culture models, both spheroids and tissue
engineered constructs [159–161,175,176]. By applying biomaterial scaffolds as artificial ECMs, the
instructive effects of substrate compositional, physical, architectural and mechanical factors has become
evident, since in these substrates, HCC cells are able to take their own morphological and tumorigenic
nature. As a remarkable example, HeG2 showed enhanced infiltrative behavior in soft scaffolds [178].
Tissue-engineered models offer complex and fascinating TMEs for HCC understanding and also more
reliable therapeutic screening, which would offer intriguing opportunities to cancer researchers in
the future.
8. Conclusion and Future Trends
Biomaterials approaches provide versatile and easily tunable properties that can be varied to treat
and study HCC. The biomaterials span a wide range from nano to macroscale for systemic delivery,
local delivery and mimicking tumor microenvironment. The application of biomaterials may be a
promising method to repurpose existing HCC drugs that may have limited effect previously through
systemic delivery. Future development of biomaterial-based implantable devices should focus on the
local delivery of a combinational therapy instead of the delivery of one traditional method alone.
Combining chemotherapy and anti-angiogenesis may result in synergistic ability of therapies
to impeded tumor growth. Zhang et al. designed a stepwise pH-responsive NP system containing
charge reversible pullulan-based (CAPL) shell and poly(β-amino ester) (PBAE)/PLGA core to deliver
of PTX and combretastatin A4 (CA4) as a combination antiangiogenesis and chemotherapy to treat
HCC [57]. Wang et al., studying methotrexate and combretastatin A4 in pH-sensitive pullulan-based
NP carrier, enhanced antitumor and anti-angiogenic effects [91]. Future work can also focus on
applying biomaterials to capture circulating tumor cells for cancer diagnosis applications. Zhao et al.
used electrospun PVA/polyethyleneimine (PEI) nanofibers through a PEG mobilized with lactobionic
acid onto for capturing hepatocellular carcinoma cells (Figure 14) [192].
Lactobionic acid can be used to capture ASGPR overexpressing HCC cells. In conclusion,
biomaterial-based applications can deliver different bioactive factors systemically and locally and
and/or serve as tissue engineering 3D models to better understand cancer biology and find more
effective therapies for HCC. Recently, primary liver cancer-derived organoids are becoming tool for
personalized biomarker identification and drug screening, owing to their ability to reflect the genetic
complexity of the tumor [192]. It has been shown that hepatic and pancreatic cancer cells can grow in the
form of organoids (also known as tumoroids) inside ECM-based gel as a natural biomaterial [193,194].
Combination of architectural cues (e.g., topography, porosity, mechanics) provided by engineered
scaffolds and specific signaling molecules, such as those obtained from cell pre-generated ECM
or lyophilized tissues, could be integrated to generate a 3D in vitro platform enabling better HCC
understanding, thus maximizing the impact for and personalized as well as precision therapies.
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Figure 14. SEM images of HepG2 cells captured onto (a) mPEG-PVA/PEI-Ac and (c)
LA-PEG-PVA/PEI-Ac nanofibers, respectively, after 240 min culture; (b,d) are high magnification
image of (a,c), respectively. Reprinted with permission from Royal Society of Chemistry, Zhao et al.,
RSC Advances, 2015 [191].
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Appendix A
Table A1. Biomaterials that have been investigated for drug delivery for liver cancer.
Form Biomaterial Bioactive Factor Targeting Agent Type of Therapy Source, Year
Nanodiamonds
Nanodiamond Carbon Epirubicin Chemotherapy Wang et al., 2014 [53]
PLGA particles
Nanoparticles (NPs)
Charge reversible pullulan-based (CAPL) shell and
poly(β-amino ester) (PBAE)/poly(lactic-co-glycolic acid)
(PLGA) core
Paclitaxel (PTX) and combretastatin A4
(CA4) Polysaccharide pullulan backbone
Anti-angiogenesis and
chemotherapy Zhang et al., 2016 [57]
NPs Poly d,l (lactide-coglycolide) (PLA) 5-fluorouracil (5-FU) Anti-SM5-1 Chemotherapy Ma et al., 2014 [56]
Microspheres Poly(d,l-lactic-co-glycolic acid) (PLGA) core surrounded by apoly(L-lactic acid) (PLLA) shell layer
Doxorubicin (DOX) and/or chitosan-DNA
NPs (chi-p53) Chemotherapy and gene therapy Xu et al., 2013 [58]
NPs Poly(gamma-glutamic acid)-poly(lactide) PTX Galactosamine Chemotherapy Liang et al., 2006 [59]
NPs biotin-/lactobionic acid modified poly(ethyleneglycol)-PLGA-poly(ethylene glycol) (BLPP) Curcumin (CUR) and 5-fluorouracil (5-FU) Biotin/lactiobionic acid Chemotherapy/Natural therapy Ni et al., 2018 [60]
Natural polymer-based particles
NPs Gelatin DOX-lactose Lactose Chemotherapy Liu et al., 2018 [65]
Microspheres Gelatin and chondroitin-6-sulfate Interleukin-2 Immunotherapy Hanes et al., 2001 [66]
NPs Chitosan None Anticancer Qi et al., 2007 [68]
NPs Chitosan None Anticancer and anti-angiogenesis Xu et al., 2010 [67]
NPs Chitosan Trans-resveratrol Biotin and avidin Phytochemicals Bu et al., 2013 [69]
NPs Chitosan
Plasmid DNA with granulocyte-macrophage
colony stimulating factor, interleukin 21,
internal ribosome entry site, and retinoic
acid early transcription factor-1
Biotin Gene therapy Cheng et al., 2017 [70]
Metallic particles
NPs Galactosylated-carboxymethyl chitosan-magnetic iron oxide(Gal-CMCS-Fe3O4)
Ras Association Domain Family 1A
(RASSF1A) gene Galactose
Gene Delivery and Chemotherapy
(Mitomycin injected as a free drug) Xue et al., 2016 [72,133]
NPs Ultrasmall superparamagnetic iron oxide SM5-1 Anti-SM51 Immunotherapy Kou et al., 2008 [73]
NPs Gold miR-375 Gold Gene therapy Xue et al., 2016 [75]
NPs Gold conjugated with sodium citrate or polyamidoaminedendrimers (PAMAM) None Gold Chemotherapy Paino et al., 2012 [74]
NPs Gold SM5-1 Gold and selective binding of SM5-1 Immunotherapy Ma et al., 2016 [78]
NPs Gold with a monolayer of L-aspartate DOX, cisplatin, capecitabine Gold Chemotherapy Tomuleasa et al., 2012 [77]
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Lipid-based particles
Liposomes Soybean phosphatidylcholine/cholesterol, (PEG)ylated DOX Lactoferrin Chemotherapy Wei et al., 2015 [79]
Liposome PEGylated liposome (liposome material unclear) DOX Targeting peptide SP94 Chemotherapy Lo et al., 2008 [82]
Immuno-liposomes
1,2-dioleoyl-3-trimethylammonium-propane (chloride salt)
(DOTAP), cholesterol,
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide
(polyethylene glycol)-2000] (DSPE-PEG-Mal),
Adriamycin (ADR) and ribonucleotide
reductase M2 (RRM2) siRNA Anti-EGFR Fab Chemotherapy and Gene Therapy Gao et al., 2013 [127]
Immuno-liposomes 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethyleneglycol)-2000] (DSPE-PEG-MAL) DOX Anti-CD147 antibody (Metuximab) Chemotherapy Wang et al., 2018 [83]
Nanomicelles Casein Berberine (BRB) and Diosmin (DSN) lactobionic acid (LA) and folic acid (FA) Phytochemicals Abdelmoneem, 2018 [85]
Liposomal NPs
Distearoylphosphatidylcholine (DSPC), cholesterol,
dioleoylphosphatidylethanolamine (DOPE),
distearoylphosphatidylethanolamine (DSPE)-mPEG2000, and
DSPE-cyclic RGDfK
DOX or triple fusion gene for molecular
imaging Anti-CD44 antibody Chemotherapy Wang et al., 2012 [84]
Lipid NPs
Cationic lipid RL01,
1,2-Distearoyl-sn-glycero-3-phosphatidylcholine (DSPC), and
1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene
glycol)-2000] (DMPE-PEG2000) and cholesterol
Anti-miR-17 Gene therapy Huang et al., 2017 [130]
Lipid NPs Trimyristin (TM), egg yolk phosphatidylcholine (ePC),galactosylated dioleoylphosphatidyl ethanolamine (Gal-DOPE) Docetaxel Galactose and lactobionic acid Chemotherapy Xu et al., 2009 [87]
Lipidoid
Ionizable lipid or cationic lipid, disteroylphosphatidyl choline,
cholesterol, and 1,2-dimyristoyl-sn-glycerol,
methoxypolyethylene glycol
siRNA for all integrin subunits in
hepatocytes Gene delivery Bogorad et al., 2014 [86]
Other Particles
NPs Hydroxyapatite Selenium Anticancer Wang et al., 2016 [88]
NPs Albumin DOX Galactosamine Chemotherapy Shen et al., 2011 [93]
NPs N-urocanyl pullulan Methotrexate and Combretastatin A4 Pullulan Anti-angiogenic and chemotherapy Wang et al., 2013 [91]
NPs Polyisohexylcyanoacrylate (PIHCA) DOX Chemotherapy Barraud et al., 2005 [94]
Dendrimer NPs
Lipids cholesterol, 1,2-distearoyl-sn-glycero-3-phosphocholine
(DSPC), and lipid PEG2000 with amine core and thiol
peripeheries
Let-7g microRNA Gene delivery Zhou et al., 2016 [95]
NPs Calcium carbonate with lipid coating Sorafenib (Sor) and miR-375 Chemotherapy and gene therapy Zhao et al., 2018 [92]
NPs Insulin multi-methacrylate DOX Targeting peptide, Cyclic RGD Chemotherapy Bibby et al., 2005 [96]
NPs Block copolymer PEG5k-PLA8k SN38 prodrug Chemotherapy Wang et al., 2018 [61]
Local Delivery
Nanofibers NPs
(immobilized on the
nanofibers)
Poly(ε-caprolactone) disulfide cross linked branched PEI
(ssPEI) PTX and miRNA-145 Chemotherapy and gene delivery Che et al., 2015 [98]
Microspheres Glass Phosphorus-32 Radiotherapy Wang et al., 2008 [97]
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Polymer millirods Poly(lactic-co-glycolic acid) PLGA
DOX
carboplatin
5-fluorouracil
Chemotherapy
Qian et al., 2002 & 2004
[101,103]
Szymanski-Exner et al.,
2003 [102]; Weinberg et al.,
2007 & 2007 [99,100]
Drug eluting beads Sulfonate-modified poly(vinyl alcohol) hydrogel DOXsor TACE, chemotherapy Pawlik et al., 2011 [109]
Drug-eluting
microspheres/beads
(DEB)
Sulfonate-modified poly(vinyl alcohol) hydrogel DOX TACE, chemotherapy Hong et al., 2006 [108]
Drug eluting beads Polyvinyl alcohol polymer modified with sulfonate groups toform a hyodrogel DOX TACE, chemotherapy Poon et al., 2007 [111]
Microspheres Poly-lactide-co-glycolide PLGA Mitomycin TACE, chemotherapy Qian et al., 2003 [110]
Biomaterials to capture cells
Nanofibers Lactobionic acid-functionalized electrospun polyvinylalcohol/polyethyleneimine via PEG spacer Diagnostic purposes Cancer diagnosis Zhao et al., 2015 [191]
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Table A2. Biomaterials that have been investigated for 3D models for studying liver cancer.
Biomaterial Type Model Cells Application Results Source, Year
Synthetic
PEG (8-arm PEG-SH) Spheroid HepG2 Spheroid formation and recovery due topolymer biodegradation with cysteine Increased cell function (albumin and urea) Moriyama et al., 2016 [159]
Polystyrene (PHP) Tissue Engineered (TE) HepG2 Structure, function and cytotoxicitystudy (methotrexate) TME bio-mimicry: bile duct formation and higher drug resistance Bokhari et al., 2007 [172]
TEOS–PDMS TE HepG2 Function under dynamic flow TME bio-mimicry: increased proliferation and aggregation capacity,higher albumin synthesis than in 2D cultures Kataoka et al., 2005 [176]
PVA TE HepG2 Function under dynamic flow TME bio-mimicry: higher albumin synthesis than in 2D cultures Kataoka et al., 2005 [176]
Biologic
Collagen Hetero-spheroid HepG2 and stromalfibroblasts Cytotoxicity study (DOX)
TME bio-mimicry: cell function (P450 activity) and increased
drug resistance Yip et al., 2013 [161]
Alginate Spheroid MHCC97L HCCLM3 Metastatic mechanism study TME bio-mimicry: increased cell maturity, in particular in metastaticcells MHCC97L Xu et al., 2013 [143]
Alginate/chitosan
blend Spheroid PLC/PRF/5 HepG2 Cytotoxicity study (DOX) TME bio-mimicry: increased malignancy and drug resistance Leung et al., 2010 [158]
Silk fibroin TE HepR21 HepG2 TME study HepR21 showed irregular aggregation and higher proliferation capacitythan HepG2 Kundu et al., 2013 [177]
Silk fibroin/chitosan TE HepG2 Liver regeneration Mechanical properties controllable, good cell proliferation She et al., 2008 [181]
Silk fibroin-lactose
(Lac-CY-SF) TE FALC-4 Liver regeneration Functional gene expression not found using collagen Gotoh et al., 2011 [175]
Composite
Decellularized human
liver tissue TE
LX2
Sk-Hep-1
HepG2
Liver regeneration Bio-compatibility and ECM remodeling Mazza et al., 2015 [179]
Alginate/decellularized
liver ECM Bead HCCLM3 Metastatic mechanism study
TME bio-mimicry: Increased cell viability and metastatic potential due to
liver ECM Sun et al., 2018 [170]
Alginate/gelatin
microspheres Spheroid HepG2
Formation of spheroids with defined size
by microsphere dissolution with MMP-9 Spheroids of 200 µm with no necrotic core Lau et al., 2012 [157]
Bioartificial
pNIPAAm-co-gelatin Spheroid Hepa/8F5 Cytotoxicity study(tamoxifen and acetaminophen)
Increased cell function (albumin CYP3A4 activity, ammonia removal) and
drug resistance Sarkar et al., 2017 [160]
Collagen-PEG/succinic
acid TE HepG2 Effect of material stiffness Higher cell cluster size and infiltration capacity in softer hydrogels Liang et al., 2011 [178]
PVA/gelatin TE HepG2 Cell migration TME bio-mimicry: tissue-like cell organization, possibility to visualizemigratory phenomena Moscato et al., 2015 [180]
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